fogsprayhk
Bicalutamide | CAS 90357-06-5 | Non-steroidal Androgen Receptor Antagonist for Prostate Cancer Research
Product Description
Bicalutamide (CAS 90357-06-5) is a potent, selective, non-steroidal androgen receptor (AR) antagonist that blocks the androgen-mediated activation of gene transcription. It has become an essential reference compound in prostate cancer research, particularly in studies exploring androgen receptor regulation, hormonal feedback mechanisms, and resistance pathways to antiandrogen therapy.
In preclinical research, Bicalutamide functions by binding to the ligand-binding domain of the androgen receptor, thereby preventing the natural ligand—testosterone or dihydrotestosterone (DHT)—from activating downstream transcriptional activity. This blockade effectively inhibits androgen-dependent cell proliferation and survival signaling in prostate and other androgen-sensitive cells. The compound is widely employed in both in vitro and in vivo models to elucidate molecular mechanisms governing hormone receptor dynamics, cell cycle progression, and apoptosis induction.
Bicalutamide’s versatility as a research reagent stems from its ability to modulate androgen receptor signaling in multiple biological contexts. Researchers employ it to study androgen receptor coactivators, nuclear translocation, gene regulation, and the emergence of antiandrogen-resistant receptor variants (e.g., AR-V7). These investigations contribute to understanding how tumor cells adapt to prolonged AR inhibition, offering insights into next-generation inhibitor development.
Bicalutamide | CAS 90357-06-5 | Non-steroidal Androgen Receptor Antagonist for Prostate Cancer Research
Product Description
Bicalutamide (CAS 90357-06-5) is a potent, selective, non-steroidal androgen receptor (AR) antagonist that blocks the androgen-mediated activation of gene transcription. It has become an essential reference compound in prostate cancer research, particularly in studies exploring androgen receptor regulation, hormonal feedback mechanisms, and resistance pathways to antiandrogen therapy.
In preclinical research, Bicalutamide functions by binding to the ligand-binding domain of the androgen receptor, thereby preventing the natural ligand—testosterone or dihydrotestosterone (DHT)—from activating downstream transcriptional activity. This blockade effectively inhibits androgen-dependent cell proliferation and survival signaling in prostate and other androgen-sensitive cells. The compound is widely employed in both in vitro and in vivo models to elucidate molecular mechanisms governing hormone receptor dynamics, cell cycle progression, and apoptosis induction.
Bicalutamide’s versatility as a research reagent stems from its ability to modulate androgen receptor signaling in multiple biological contexts. Researchers employ it to study androgen receptor coactivators, nuclear translocation, gene regulation, and the emergence of antiandrogen-resistant receptor variants (e.g., AR-V7). These investigations contribute to understanding how tumor cells adapt to prolonged AR inhibition, offering insights into next-generation inhibitor development.